FluoroPharma Medical, Inc. (FPMI) Continues to Move New Products Forward
Turning a good idea into a money making product can be a formidably expensive project, especially when dealing with medical substances to be introduced to the human body. FluoroPharma, developer of medical diagnostic imaging agents for use with PET (positron emission tomography) scanning, is believed to be in a strong position to accomplish exactly that with its two primary imaging assets, CardioPET and BFPET. CardioPET is an imaging agent designed for cardiac viability assessment, detecting regions of metabolic insufficiency. BFPET is designed for myocardial perfusion imaging, measuring cardiovascular blood flow. The company is about to take both of these products…